Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer by Gottardi, R & Douradinha, B
Gottardi and Douradinha Journal of Nanobiotechnology 2013, 11:30
http://www.jnanobiotechnology.com/content/11/1/30REVIEW Open AccessCarbon nanotubes as a novel tool for vaccination
against infectious diseases and cancer
Riccardo Gottardi1,2,3† and Bruno Douradinha1,4*†Abstract
Due to their unusual properties, carbon nanotubes have been extensively employed in electronics, nanotechnology
and optics, amongst other. More recently, they have also been used as vehicles for drug and antigen delivery, the
latter being a novel immunization strategy against infectious diseases and cancer. Here we discuss the potential of
carbon nanotubes as an antigen delivery tool and suggest further directions in the field of vaccination.
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Carbon nanotubes (CNT) are probably the most famous
members of the fullerenes family. Fullerenes comprise
any molecule made entirely of carbon atoms, shaped as
a sphere, an ellipsoid, or a tube [1]. In 1991, Ijima and
colleagues published in Nature their description of
“helical microtubules of graphitic carbon” [2]. CNT are
generally distinguished between single walled carbon
nanotubes (SWNT) and multiwall carbon nanotubes
(MWNT). The former can be conceptualized as a seam-
less cylinder obtained by rolling up a single sheet of
graphite generally referred to as a graphene layer, i.e., a
plane of carbon atoms arranged in a hexagonal lattice.
MWNT can be thought as the coaxial assembly of dif-
ferent SWNT of different diameters, one contained
within each other. The characteristic aspect ratio of
CNT is in the order of millions to one, as their length
can span hundreds of microns whereas their diameter is
only few nanometers across, and down to less than
0.8 nm for the smaller SWNT. Because of their unique
geometry, CNT are often referred to as “one dimen-
sional” [3] and even “zero dimensional” [4] objects.
Their nanometer lateral dimensions are the basis of
several of the desirable properties of CNT. However,
they also represent a potential limitation, contributing to
the inherent difficulties of working with CNT. In fact,* Correspondence: brd49@pitt.edu
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article, unless otherwise stated.pristine nanotubes are virtually insoluble in most sol-
vents in ordinary conditions [5], which limits their large
scale processability. Consequently, a large amount of re-
search has been devoted to develop processes that could
render CNT soluble, from functionalization of their
hydropholbic sidewalls with soluble molecules [6], to
wrapping individual CNTs with polymers [7] or DNA
[8] and to reduce their length so their dispersibility can
be increased [4,9]. Since their popularization in the early
‘90s, CNT have sparked a great deal of excitement in the
scientific community and beyond, due to their unique
properties, with potential to revolutionize the fields of
material science, electronics, energy collection and sto-
rage, medicine and many more. CNT have unmatched
tensile strength [10], which makes them the strongest
material yet discovered, and great thermal conductivity
along their axis [11]. In biomedical applications, CNT
are mainly investigated either to enhance molecular
biosensing [12], due to their optoelectronic properties
[13-15], or as drug delivery agents [16]. Since CNT are
readily internalized by cells [17], they are ideal vehicles
for delivery of therapeutics [18] or diagnostics [19].
CNT can bind macromolecules such as proteins and oli-
gosaccharides, which suggest they would have potential
applications as carriers for delivery of active molecules,
like drugs or antigens [20-22].
The functionalization of CNT is paramount, first to
guarantee the solubility of CNT in aqueous solutions,
crucial in a biological context and second, to ensure that
the desired molecular agent, either a drug or a marker, is
bound to the nanotube. As mentioned above, CNT areMed Central Ltd. This is an Open Access article distributed under the terms of
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use as a delivery agent for medicinal purposes [23]. Some
approaches were then developed to improve their solubi-
lity. The most used is covalent functionalization, in which
the desired active molecules bind to cationic functional
groups, the latter bound either on the surface or within
the walls of CNT. Examples of functional groups are
polyethylene glycol (PEG) or ammonium-terminated trie-
thylene glycol, which is a reactive intermediate that allows
the synthesis of several functionalized CNT mixtures. Bio-
molecules such as oligonucleotides and proteins were also
used to functionalize CNT. The functional groups are
bound to the active molecules, increasing the solubility of
CNT [24]. Furthermore, sugar moieties like starch and
oligomers like polyvinylpyrrolidone wrap around CNT
and transport them to the aqueous phase [7,22]. Both
nanotube-mediated oligonucleotide transport inside living
cells [25] as well as plasmid DNA gene delivery [26] have
shown promising results, which might open the way to
the use of CNT as non-viral delivery vectors. The use of
CNT carriers could in fact overcome some of the limita-
tions of other non-viral vectors available today, namely
the poor pharmacokinetic profiles of the administered
oligonucleotide and plasmid DNA conjugates, and the
low levels of gene expression obtained [27].
Carbon nanotubes induce specific and protective Immune
responses
An effective vaccine must induce a potent immune res-
ponse, either at cellular level, stimulating cytotoxic T cells
which target and destroy infected cells or at humoral level,
through stimulation of the production of neutralizing anti-
bodies which promote opsonization and consequent
pathogen clearance. Vaccines against some pathogens, like
HIV or Malaria, due to their complexity, would require
both responses to be fully efficient in preventing infection
and eliminating circulating pathogens. Innate immune
responses are also important in vaccination, since they
play a crucial role in antigen presentation and immune
cells recruitment to infection sites [28].
Several cell types can uptake CNT, including cells of the
immune system, such as macrophages, monocytes, natural
killer (NK), dendritic cells, T and B cells [17,29-34]. In
most cases, CNT did not impair functionality of these
cells and it was observed that functionalized CNT are less
toxic than pristine CNT, inducing therefore a lesser cyto-
toxic response [17,35]. CNT were shown to activate cells
from the innate immune system, such as monocytes
[29,31,34], macrophages [31,32,34] and dendritic cells
[30]. Microarray profiling of a monocytic cell line,
THP-1, showed that CNT, both functionalized and non-
functionalized, activate several genes involved in mono-
cyte response to infection or vaccination, such as nuclear
factor kappa-light-chain-enhancer of activated B cells(NF-κB), interleukin-1β (IL-1β), IL-6, tumor necrosis
factor-α (TNF-α), among others [29,31]. However, the
non-functionalized CNT also increased the expression of
genes related to oxidative stress and apoptosis [31]. The
functionalized CNT were oxidized and further modified
to incorporate ammonium; both versions with and with-
out ammonium were studied, as different diameters (from
9.5 nm to 30 nm). These nanotubes were shown to be
non-toxic to both THP-1 cells and human primary mono-
cytes and to induce the production of chemokines in those
cells (IL-1β, IL-6,TNF-α and IL-10) [29,35]. These chemo-
kines are involved in many processes, namely recruitment
of T cells to infection sites and inflammation. Interestingly,
CNT of low diameter (9.5 nm) and lacking the ammo-
nium group failed in activating the pathways above men-
tioned and also in inducing production of chemokines in
monocytes [29]. These studies suggest that CNT are able
to induce an innate immune response dependent both on
their functionalization type and size. Macrophages derived
from THP-1 cells presented the same phenotype as just
described for monocytes [31].
Antigen presentation is a process crucial to mount an
immune response against foreign antigens or tumor anti-
gens. Professional antigen presenting cells (APC), such as
dendritic cells or macrophages, will uptake a source of
antigen (a microorganism, an infected or tumor cell, or a
vaccine carrier, such as CNT), degrade it and present it to
T cells through the surface complexes MHC class I or
class II. While MHC class I induces a more cytotoxic
CD8+ T cell response, MHC class II shifts the immune
response to helper CD4+ T cells which will promote an
antibody based response [28]. CNT activate both MHC
class I and class II, the latter to a greater extent [30,36],
suggesting they will induce preferably a humoral response.
CNT carrying peptides of immunogens of some pathogens
or tumors have been shown to be immunogenic and
protective in experimental animal models. CNT con-
taining either peptides for a B cell epitope from the foot-
and-mouth disease virus (FMDV), which causes huge eco-
nomic losses in the cattle industry [37], or the N-terminal
(residues 21–42) of Plasmodium vivax Apical Membrane
Antigen-1 (AMA-1, a micronemal protein highly con-
served amongst Plasmodium species, the causative agent
of Malaria [28,38]), induced a high titer of antibodies
[23,39]. Further tests confirmed that the antibodies gene-
rated were specific for the regions present in the CNT.
They were able to fully neutralize the FMDV infection
in vitro and some of the animals immunized with the
Plasmodium vivax AMA-1 N-terminal were fully pro-
tected against challenge with a murine plasmodial species,
Plasmodium berghei, both sharing a high homology for
that AMA-1 region [23,39]. A very recent work showed
that a peptide of Wilm’s tumor protein 1 (WT1), a kidney
cancer, conjugated to SWNT is rapidly internalized by
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[30]. The SWNT conjugated WT1 peptides were interna-
lized through a macropinocytosis mechanism, known to
uptake several macromolecular antigens in immature den-
dritic cells. They were found to co-localize in lysomal
compartments, which lead to the degradation of antigens
and promote their presentation to the immune system
through MHC class II molecules. Both conjugated and
unconjugated WT1 peptide elicited a similar CD4+ T cell
interferon-γ (IFN-γ) dependent response in human lym-
phocytes. However, SWNT conjugated peptides induced a
much higher humoral response in Balb/c mice when
TiterMax, a commercial adjuvant, was used. This is of
particular importance, since tumor self-antigens usually
induce poor immune responses.
As mentioned above, CNT can also activate MHC class
I receptors [36], which would induce a cytotoxic, Th1
biased cell response, characterized by the production of
cytokines such as IFN-γ, TNF-α and IL-12. Although pris-
tine CNT do not induce a CD8+ T cell response, there is
indirect evidence that functionalized, conjugated SWNT
and MWNT originate such response. Zeinali and col-
leagues tested SWNT coated with tuberculin purified pro-
tein derivative (PPD), a mixture of antigens derived from a
culture of Mycobacterium tuberculosis, the pathogen
responsible for tuberculosis [40]. Balb/c mice were immu-
nized with tuberculin PPD, either free or bound to SWNT,
receiving two immunizations, 2-weeks apart. Two groups
were immunized with free tuberculin PPD, one adjuvanted
with complete Freund’s adjuvant (CFA) while the other
received no adjuvant. The authors did not assess protec-
tion against challenge with an infectious bacillus, but com-
pared the cytokine profile induced by the immunization
with tuberculin, free or attached to SWNT, with the one
elicited by immunization with BCG (a tuberculosis vac-
cine based on attenuated Mycobacterium bovis). The levels
of IFN-γ, IL-12, IL-5 and IL-10 were measured in the cul-
tures of splenocytes isolated from the immunized mice.
Both groups immunized with BCG and tuberculin PPD
bound to SWNT had significantly higher levels of IFN-γ
when compared to mice immunized with free tuberculin,
adjuvanted or not with CFA. Conversely, the latter groups
had significantly higher levels of Th2-type cytokines (IL-5
and IL-10) than the BCG and SWNT immunized groups.
Another work shows evidence of cytotoxic T cells induced
by CNT. Meng and colleagues conjugated proteins from
cellular lysates derived from the murine H22 liver cancer
to previously oxidized MWNT [41]. Balb/c mice
immunized with a tumor cell vaccine (TCV) based on the
H22 liver cancer cells and with MWNT containing
proteins of the same cells had a higher cure rate than
those immunized with just TCV or TCV together with
non-conjugated nanotubes. Also, immunized mice were
protected upon further challenge with H22 liver cancer,never developing cancer unlike control mice. Further-
more, the protection observed was specific, since mice
challenged with a different tumor cell line were not
protected. Moreover, lymphocytes isolated from immu-
nized mice targeted H22 liver cells, but not the other
tumor cell line.
Overall, more work is required to fully understand the
action of CNT on the immune system. However, the
works described above show clearly that CNT activate
the innate immune response, as observed by the tran-
scription of genes involved in several pathways of in-
flammation, response to infection and vaccination and
release of chemokines which will attract APC and conse-
quent mount an adaptive immune response. Macro-
phages and dendritic cells process efficiently peptides
incorporated in CNT and present them in MHC Class I
and II, promoting preferably a humoral response against
antigens conjugated to them, but also a cellular immune
response. CNT were not immunogenic by themselves,
since no specific immune response for them was ob-
served [29,30], indicating they can be used when regi-
mens of multiple immunizations are required without
risk of losing their stimulatory properties.
Carbon nanotubes as potential adjuvants
Many vaccines use adjuvants, substances that enhance
the immunogenic potential of the immunization stra-
tegy, without inducing an immune response per se [28].
As described above, CNT stimulate the innate immune
system, therefore having inherent adjuvant properties
[29,31]. Another work showed that, when administration
of embryonic stem cells (ESC) is adjuvanted with MWNT,
the therapeutic effect of the former in a colon cancer
C57Bl/6 mouse model is enhanced [42], promoting a
decrease in the tumor volumes and an increase in cyto-
toxic CD8+ T cells and Th1-type cytokines, such as IFN-γ
and IL-2.
It has been suggested that SWNT conjugated with
unmethylated CpG DNA motifs can be used as an adju-
vant in vaccines [43]. These DNA motifs can be consi-
dered a danger signal by the immune system, recognized
by Toll-like receptor 9 (TLR-9), an endocytic receptor,
and confer protection against several intracellular patho-
gens and tumors by improving the immune response
against them. However, the action of the sole CpG DNA
motifs is short-lived and requires administration of high
and constant doses, due to the fact both CpG and cellu-
lar membranes have a negative charge, impairing the up-
take of the former by the cells. Bianco and colleagues
conjugated a CpG motif in SWNT, improving their
immunostimulatory properties. When incubated with
mouse splenocytes, CpG 1668 conjugated to SWNT
leads to a decrease in the production of IL-6, compared
with the non-conjugated form. Since this cytokine is
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CpG conjugated with SWNT would be less toxic than
using the CpG alone. Also, the SWNT would compen-
sate for the negative charge of the CpG, facilitating its
entry in the cells. Another work showed that CpG con-
jugated with functionalized SWNTs (CpG-SWNT) were
avidly internalized by immune cells in a mouse brain
tumor (gliomas) model [34]. Unlike the previous work, a
pro-inflammatory cytokine response was observed, as
shown by the increase in the production of IL-12 and
TNF-α by monocytes which suffered uptake of CpG-
SWNT. NK cells, macrophages and microglia (APC
resident in brain vasculature) also readily uptake
CpG-SWNT, resulting in eradication of gliomas in more
than 50% of the animals and long lasting immunity
when cured mice were re-challenged with homologous
tumor. Protection was dependent on NK and CD8+ T
cells. Neither administration of CpG alone nor CpG co-
administrated with unconjugated CNT mimicked these
results. This work illustrates the potential of CNT to
deliver adjuvant molecules (in this case, CpG) in a
mouse model of gliomas, clearly contributing to clea-
rance and immunization against this tumor, and suggests
the use of this strategy as adjuvants either for other
tumors or even for intracellular pathogens.
Toxicity of carbon nanotubes
One of the main concerns regarding the use of CNT in
vaccines and other human therapeutic or prophylactic
interventions is their toxicity. Due to their small size,
they can spread within the organism, reaching several
crucial sites, which represents both a concern in terms
of cytoxicity and an opportunity in terms of their poten-
tial as vaccine carriers. Several evidences show that CNT
can be toxic both in vitro and in vivo, inducing the pro-
duction of cytotoxic reactive oxygen species (ROS), cell
apoptosis and necrosis [24,44,45]. It has also been shown
that CNT can bind to several plasma proteins and can
activate the innate immune system complement path-
ways, leading to inflammation [46]. Although this could
have an adjuvant effect, in excess it could be deleterious
for the host if high levels of inflammation are induced.
However, the toxicity of CNT is dependent of several
factors, namely the dose used and their solubility in
water. Unsurprisingly, the higher the dose, the more
pronounced are the toxic effects. It could in fact be
argued that for most compounds, very high doses induce
a toxic effect. Furthermore, CNT that are functionalized
in order to be more soluble in water are less toxic [16].
In particular, PEG or PEG-phospholipid dispersed CNT
were shown to be well tolerated in biological systems
both in vivo and in vitro [44,47]. Functionalized CNT
are also more biocompatible in mice, being slowly
excreted through urine and feces, therefore being lessprone to potential toxic effects caused by accumulation,
and are also more hemocompatible, since hematological
analyses show no major differences between naïve animals
and mice subjected to CNT [44,45,48,49]. Additionally, an
accurate purification of CNT to ensure toxic chemicals or
metals used during their production and in the func-
tionalization steps are effectively removed, also reduces
their toxicity. However, this process is very laborious and
complex. Overall, the actual level of toxicity of CNT, as
shown in the literature and assessed by our own expe-
rience, remains controversial and studies with established
toxicology models have still to be optimized and im-
plemented [16].
It is important to note that the majority of the works
mentioned above, do not report any adverse effect of
CNT in cells or mice, including those that specifically
addressed the issue of toxicity. For the tuberculin PPD
study, Zeinali and colleagues showed that although
SWNT generate ROS in Balb/c mice splenocytes, it had
no effect in the cell viability [40]. Also, nitric oxide, an end
product of inducible nitric oxide synthase, which would
be an indication of an inflammatory response, could not
be detected in the supernatants of mouse macrophage
cultures previously incubated with SWNT alone or conju-
gated with PPD. Moreover, immature dendritic cells incu-
bated with doses of SWNT up to 100 μg/mL were not
affected in their functionality and viability [30].
Toxicity also varies according to the different routes
of administration [44,45]. Non-dispersed CNT tend to
form larger aggregates and therefore are more toxic.
Works with pristine CNT administered through the
respiratory tract in animal models show a high degree of
inflammation, granuloma formation and obstruction of
the upper airways [31,45,50]. Even functionalized CNT
seem to induce toxicity in lungs in rats [51]. Although
some strategies were shown to circumvent the issue of
toxicity following intranasal administration, such as
CNX NT, nanotubes doped with nitrogen groups [52],
the risk of mechanical obstruction may persist, making
this route less appealing for immunization with CNT.
Administration of pristine CNT subcutaneously and
intraperitoneally in mice also led to undesired toxic
effects, such as granuloma formation or inflammation
[45,53,54]. Conversely, when CNT which suffered
several functionalization methods (e.g., PEG, amino
acids, etc.) were injected in mice using the same routes,
only in some cases low levels of inflammation were ob-
served [23,30,39-41,44,55,56]. Oral administration of
both pristine and functionalized CNT did not induce
toxicity in mice [44,45,53,57,58].
An useful overview of the concerns related to toxicity
in the biomedical applications of nanotubes and the
related regulatory issues has been elegantly discussed
elsewhere [59].
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It is clear that CNT have a high potential for delivery of
antigens and to be considered as a novel vaccine plat-
form for both infectious diseases and cancer, due to the
promising results mentioned above. Their nanometric
dimension allows them to be easily internalized by cells.
They have a large inner volume compared to their linear
dimensions and biomolecules can be easily immobilized
on their outer surface. Such confers them an advantage
to be used as nanocarriers for controlled and targeted
drug delivery [59]. As stated, further studies regarding
the toxicity of these nanostructures are required and
new approaches are being undertaken to enhance the
capacity of cells to degrade CNT, such as shortening of
CNT [4]. Their immunization potential can be improved
upon confirmation that the conjugated epitopes main-
tain their correct conformation, a key aspect for an
efficient immune response elicited against them [60].
Furthermore, the recent discovery that certain enzymes
such as myeloperoxidases can degrade CNT leads to
believe that, if antigens are encapsulated within these
nanostructures, they would be more protected from
external factors [61]. After cellular internalization and
degradation of CNT, antigens could still be efficiently
presented. Functionalized CNT can be administered
using routes commonly used in vaccination, such as sub-
cutaneous and oral without inducing severe, undesired
toxic effects [23,30,39-41,44,55-57] which strengthens the
possibility of their usefulness as immunization strategies.
Nevertheless, the promise of CNT to revolutionize the
field of biomedical applications is yet unmet. In fact, as
clearly described by Kostarelos and colleagues “The use
of CNT in medicine is now at the crossroads between a
proof-of-principle concept and an established preclinical
candidate for a variety of therapeutic and diagnostic
applications. Progress towards clinical trials will depend
on the outcomes of efficacy and toxicology studies,
which will provide the necessary risk-to-benefit assess-
ments for carbon nanotube based materials” [16].
Whether CNT will meet these expectations is at the mo-
ment difficult to predict, but everything indicates most
probably they will. Not long ago, the use of CNT in
material science applications was even regarded as some
science fiction tool [62]. However, nowadays, yarns of
nanotubes are routinely produced in an up scalable
process [63], and can be woven to form ropes and fab-
rics with exceptional properties [64]. Current and further
research will definitely unravel the potential of CNT to
be used in vaccination approaches against infectious
diseases and cancer.
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